(MDT) Medtronic - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 103.134m USD | Total Return: -5.7% in 12m
Avg Turnover: 858M
EPS Trend: 76.2%
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Medtronic PLC is a global leader in medical technology, specializing in device-based therapies across four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company manufactures a diverse range of critical hardware, including pacemakers, spinal implants, surgical robotics, and continuous glucose monitoring systems. Headquartered in Ireland, Medtronic serves a broad spectrum of medical specialists and healthcare systems worldwide.
The medical device industry operates within a high-barrier-to-entry environment due to intensive R&D requirements and stringent regulatory approval processes from bodies like the FDA. Medtronic utilizes a diversified business model that balances mature, high-volume products like surgical staples with high-growth innovation areas such as AI-powered surgical analytics and remote patient monitoring software.
To deepen your understanding of these business segments, consider reviewing the detailed financial breakdowns available on ValueRay.
- Regulatory approval and adoption of Hugo robotic-assisted surgery system drive long-term growth
- Continuous glucose monitoring innovation and insulin pump integration determine diabetes segment market share
- Cardiovascular portfolio revenue depends on procedure volumes and transcatheter aortic valve replacement demand
- Global supply chain stability and healthcare labor shortages impact manufacturing costs and margins
| Net Income: 4.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 40.08% < 20% (prev 31.82%; Δ 8.26% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.33b > Net Income 4.80b |
| Net Debt (27.0b) to EBITDA (9.43b): 2.86 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2% |
| Gross Margin: 65.02% > 18% (prev 65.31%; Δ -0.30% > 0.5%) |
| Asset Turnover: 40.08% > 50% (prev 37.27%; Δ 2.81% > 0%) |
| Interest Coverage Ratio: 9.04 > 6 (EBIT TTM 6.47b / Interest Expense TTM 715.0m) |
| A: 0.16 (Total Current Assets 24.1b - Total Current Liabilities 9.49b) / Total Assets 91.5b |
| B: 0.35 (Retained Earnings 32.3b / Total Assets 91.5b) |
| C: 0.07 (EBIT TTM 6.47b / Avg Total Assets 90.7b) |
| D: 1.16 (Book Value of Equity 49.0b / Total Liabilities 42.3b) |
| Altman-Z'' = 3.89 = AA |
| DSRI: 0.10 (Receivables 87.0m/6.12b, Revenue 36.4b/33.5b) |
| GMI: 1.00 (GM 65.31% / 65.02%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.08 (Revenue 36.4b / 33.5b) |
| TATA: -0.03 (NI 4.80b - CFO 7.33b) / TA 91.5b) |
| Beneish M = -3.72 (Cap -4..+1) = AAA |
As of June 16, 2026, the stock is trading at USD 80.38 with a total of 6,407,736 shares traded.
Over the past week, the price has changed by -0.38%,
over one month by +5.55%,
over three months by -8.16% and
over the past year by -5.67%.
Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 98.6 | 22.6% |
P/E Trailing = 21.5362
P/E Forward = 13.459
P/S = 2.8362
P/B = 2.1033
P/EG = 1.5828
Revenue TTM = 36.4b USD
EBIT TTM = 6.47b USD
EBITDA TTM = 9.43b USD
Long Term Debt = 27.8b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 58.0m
Net Debt = 27.0b USD (calculated: Debt 28.1b - CCE 1.15b)
Enterprise Value = 130b USD (103b + Debt 28.1b - CCE 1.15b)
Interest Coverage Ratio = 9.04 (Ebit TTM 6.47b / Interest Expense TTM 715.0m)
EV/FCF = 23.98x (Enterprise Value 130b / FCF TTM 5.43b)
FCF Yield = 4.17% (FCF TTM 5.43b / Enterprise Value 130b)
FCF Margin = 14.92% (FCF TTM 5.43b / Revenue TTM 36.4b)
Net Margin = 13.20% (Net Income TTM 4.80b / Revenue TTM 36.4b)
Gross Margin = 65.02% ((Revenue TTM 36.4b - Cost of Revenue TTM 12.7b) / Revenue TTM)
Gross Margin QoQ = 75.86% (prev 64.89%)
Tobins Q-Ratio = 1.42 (Enterprise Value 130b / Total Assets 91.5b)
Interest Expense / Debt = 2.54% (Interest Expense 715.0m / Debt 28.1b)
Taxrate = 21.17% (1.30b / 6.14b)
NOPAT = 5.10b (EBIT 6.47b * (1 - 21.17%))
Current Ratio = 2.54 (Total Current Assets 24.1b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.1b / totalStockholderEquity, last quarter 49.0b)
Debt / EBITDA = 2.86 (Net Debt 27.0b / EBITDA 9.43b)
Debt / FCF = 4.97 (Net Debt 27.0b / FCF TTM 5.43b)
Total Stockholder Equity = 48.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.29% (Net Income 4.80b / Total Assets 91.5b)
RoE = 9.92% (Net Income TTM 4.80b / Total Stockholder Equity 48.4b)
RoCE = 8.49% (EBIT 6.47b / Capital Employed (Equity 48.4b + L.T.Debt 27.8b))
RoIC = 6.29% (NOPAT 5.10b / Invested Capital 81.0b)
WACC = 5.65% (E(103b)/V(131b) * Re(6.65%) + D(28.1b)/V(131b) * Rd(2.54%) * (1-Tc(0.21)))
Discount Rate = 6.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: -1.47%
[DCF] Terminal Value 76.04% ; FCFF base≈5.33b ; Y1≈5.56b ; Y5≈6.35b
[DCF] Fair Price = 55.32 (EV 98.0b - Net Debt 27.0b = Equity 71.0b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 4.65% → 2.50% )
EPS Correlation: 76.20 | EPS CAGR: 2.32% | SUE: -0.72 | # QB: 0
Revenue Correlation: 97.27 | Revenue CAGR: 4.84% | SUE: 3.20 | # QB: 4
EPS current Quarter (2026-07-31): EPS=1.39 | Chg30d=+0.52% | Revisions=+18% | Analysts=24
EPS next Quarter (2026-10-31): EPS=1.35 | Chg30d=-5.80% | Revisions=-83% | Analysts=24
EPS current Year (2027-04-30): EPS=5.95 | Chg30d=N/A | Revisions=-86% | GrowthEPS=+7.5% | GrowthRev=+6.9%
EPS next Year (2028-04-30): EPS=6.41 | Chg30d=N/A | Revisions=-78% | GrowthEPS=+7.8% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -86%